Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression By Ogkologos - July 16, 2025 767 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATRACTIB study Source RELATED ARTICLESMORE FROM AUTHOR Cancer vaccines and the next frontier in melanoma: From headlines to scientific evidence Five-Year Survival Outcomes with Neoadjuvant Therapy in Melanoma Demonstrate that Neoadjuvant ICIs Exceeded Adjuvant Benchmarks Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor MOST POPULAR Doing More—Together—to End Cancer as We Know It February 9, 2023 Coping With Advanced Melanoma and a Second Cancer Diagnosis: A Survivor’s... June 22, 2023 6 of the biggest good news cancer stories of 2021 December 15, 2021 Can Eating Soy Cause Breast Cancer? October 19, 2021 Load more HOT NEWS Coffee Shop Owner Runs Competitor’s Business For Free After Hearing He... Pride 2023: Taking on the inequalities in LGBTQ+ cancer care Survivor Sees Mom Fighting Breast Cancer At Brunch And Pays For... Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated...
